<DOC>
	<DOC>NCT02968160</DOC>
	<brief_summary>This is a Randomized, open-label, 2 groups, parallel design.</brief_summary>
	<brief_title>A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome</brief_title>
	<detailed_description>This study objective is to compare the safety and efficacy between fixed dose combination (Duowell® tab) and free pill combination therapy of Telmisartan and Rosuvastatin in hypertensive and hypercholesterolemic patients with metabolic syndrome.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Aged between 19 and 79 years old at screening visit Subjects who have being used antihypertension drugs and Lipid lowering agents over 4weeks before randomization. Subjects who have been diagnosed with metabolic syndrome according to following criteria Definition of patients with metabolic syndrome: Patients satisfy two of the following criteria at least Abdominal obesity: Waist measurement &gt; 90 cm(male), &gt; 80 cm(female) Triglyceride(TG) ≥ 150 mg/dL( HighDensity Lipoprotein Cholesterol(HDLC) &lt; 40 mg/dL(male), &lt; 50 mg/dL (female) Fasting Plasma Glucose(FPG) ≥ 100 mg/dL or Subject who has being used oral hypoglycemic agents Childbearing potential women have certainly negative of the pregnancy test at screening visit (visit 1), and agree to implement the effective contraception during the study period(including the medically nonpregnant state) Subjects who have signed after fully understanding the purpose, content, characteristics and risk of the investigational product and get explained enough. Subjects who taking antihypertension drugs more than three agent Subjects who have mean Sitting Systolic Blood Pressure(siSBP) &gt; 160 mmHg (excluded if appliable, one of the arms) Subjects who have blood pressure ≥ 140/90 mmHg with taking 2 or more antihypertension drugs (except if any of the arms) Subjects that Low Density LipoproteinCholesterol(LDLC) isn't properly controlled according to National Cholesterol Education Program Adults Treatment Panel (NCEP ATP) III criteria Subjects who have triglyceride (TG) ≥ 400mg/dL Subjects who have a difference more than 20mmHg at the mean Sitting Diastolic Blood Pressure(siSBP) measured three times in both arms. Other exclusions applied</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>